PPT-3D (Paritaprevir-Ritonavir-

Ombitasvir Dasabuvir RBV in GT1b PEARLII Phase 3 Treatment Experienced Andreone P et al Gastroenterology 201414735965 Source Andreone P et al Gastroenterology 201414735965. TURQUOISE-II. Phase 3. . Treatment. Naïve and Treatment . Experienced. Poordad. F, et al. N . Engl. J Med. 2014;370:1973-82.. Compensated Cirrhosis. Source: . Poordad. F, et al. N . Engl. J Med. 2014;370:1973-82.. -Ritonavir. -Ombitasvir . + Dasabuvir) . + RBV in . GT1. SAPPHIRE-II. Phase . 3. Treatment. . Experienced. Zeuzem. S, . et al. N . Engl. J Med. . 2014;370:1604-14.. Source: . Zeuzem. S, et al. N . OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + RBV. Randomisation*. 1 : . 1. Open-label. 18-70 years. HCV genotype 1. HCV RNA ≥ 10,000 IU/ml. Naïve or pre-treated with PEG-IFN + RBV. HIV infection, on ATV/. OBV/PTV/r . + . DSV . + RBV. OBV/PTV/r + . DSV . + RBV. Randomisation**. 1 : 1. Open-label. 18-70 years. HCV genotype 1. Naïve or pre-treated. Cirrhosis*. Child-Pugh A < 7. HCV RNA ≥ 10,000 IU/ml. OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + RBV. Randomisation*. 1 : . 1. Open-label. 18-70 years. HCV genotype 1. HCV RNA ≥ 10,000 IU/ml. Naïve or pre-treated with PEG-IFN + RBV. HIV infection, on ATV/. Paritaprevir. -. Ritonavir. . and . Dasabuvir. +/- RBV in GT1. PEARL-III and PEARL-IV. Phase 3. . Treatment. . Naïve. Ferenci. P, et al. N . Engl. J Med. 2014;370:1983-92.. Source: . Ferenci. . . + Dasabuvir) + RBV in GT1 . TURQUOISE-I. Phase . 2 . Treatment. Naïve and Treatment . Experienced. Wyles. D, et al. 65. th. AASLD. 2014: Abstract . 1939. . . HIV Coinfection. Source: . Wyles. D, et al. 65. Updated: . July . 6. , . 2015. Treatment of Hepatitis C in Patients with Renal Insufficiency. Robert G. Gish MD. Professor Consultant, Stanford University Medical Center. Senior Medical Director, St Josephs Hospital and Medical Center, Liver Program, Phoenix, Arizona. PATENTSCOPE. September. 2016. Sandrine Ammann. Marketing & Communications Officer. To this webinar:. Chemical structure search. Agenda. Chemical structure search. Timeline. Access . How . does. . DSV . placebo. Randomisation*. Partial blind. 18-70 years. Chronic HCV infection. Genotype 1 . Treatment-naïve. HCV RNA > 10,000 IU/ml. No cirrhosis. No HBV or HIV co-infection. * Randomisation 1:2 if genotype 1a (PEARL-IV) ; . APM Resident Education Curriculum. Karina . Uldall. MD, MPH . Inpatient Psychiatry and Psychosomatic Medicine . Section Head, Virginia Mason Hospital Psychiatry Consultation Service. Updated. Fall 2013. AI424-043 . Study. Atazanavir vs. Lopinavir-ritonavir in Previous PI Failure . AI424-043. : Study Design. Source: . Cohen C, et al. . Curr Med Res Opin. . 2005;21:. 1683-92.. Atazanavir 400 mg once daily + 2 NRTIs. Study 105. Atazanavir + [Cobicistat or Ritonavir] + TDF-FTC (Phase 2). Study 105: Study Design. Source: . Elion. R, et al. AIDS. 2011;25:1881-6. . Background. : Randomized, partially placebo-controlled, double-blind phase 2 trial to compare the safety and efficacy of cobicistat and ritonavir as pharmacokinetic enhancers administered with atazanavir and fixed-dose tenofovir DF-emtricitabine in treatment-naïve adults with HIV infection. NEAT001/ANRS 143 Trial. Darunavir/r + Raltegravir versus Darunavir/r + TDF-FTC. NEAT001/ANRS143: Study Design. Source: . Raffi. F, et al. Lancet. 2014;384:1942-51. .. Darunavir + Ritonavir QD. + Raltegravir BID .